The FDA approved Novo Nordisk’s Ozempic to treat chronic kidney disease in patients with Type 2 diabetes, expanding its use beyond diabetes management. This approval allows Ozempic to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in this patient population. A late-stage trial demonstrated Ozempic significantly reduced severe kidney outcomes by 24%, slowed kidney function decline, and lowered cardiovascular event risk. The approval highlights the broader health benefits of GLP-1 drugs, impacting treatment for comorbid conditions frequently found together.
Read More
Due to resolved shortages of Eli Lilly’s weight-loss and diabetes medications, Zepbound and Mounjaro, the FDA has ordered a phase-out of copycat versions sold by specialty and online pharmacies. This decision, effective within 60-90 days, benefits Lilly and potentially impacts patient access and costs. The FDA cited improved supply and safety concerns regarding the compounded drugs as reasons for the action. This reversal follows an earlier decision that was met with public opposition and legal challenge.
Read More
Novo Nordisk’s recent announcement to slash US list prices of two insulin products by more than 70% is undeniably a significant event. This dramatic price reduction, while seemingly a benevolent act, is a complex issue with multiple contributing factors beyond simple corporate altruism.
The timing of this price cut is intriguing, coinciding with the Biden administration’s negotiations with pharmaceutical companies to lower Medicare drug prices. While the full effects of these negotiations won’t be felt until 2026, Novo Nordisk’s proactive move suggests a response to the broader pressure for affordability in the insulin market. It’s tempting to see this as a direct result of political pressure, and perhaps it partially is, but it’s likely more nuanced than that.… Continue reading
John Q. Hosedrinker 
Matt Underwood